Type IIF Congenital Disorder Of Glycosylation

mutation in SLC35A1

Also Known As:

Congenital Disorder Of Glycosylation, Type IIF; CDG IIF; CDG2F; CDGIIF

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neutropenia
2.	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)

1.	Martínez-Duncker, Iván: 1 article (12/2016)
2.	Mollicone, Rosella: 1 article (12/2016)
3.	Salinas-Marín, Roberta: 1 article (12/2016)

Drugs and Important Biological Agents (IBA) related to Type IIF Congenital Disorder Of Glycosylation:

1.	AntigensIBA 12/01/2016 - "In 2005, we reported a novel Congenital Disorder of Glycosylation (CDG) termed CDG-IIf or SLC35A1-CDG, characterized by macrothrombocytopenia, neutropenia and complete lack of the sialyl-Lex antigen (NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAc-R) on polymorphonuclear cells. "
2.	Sialyl Lewis X AntigenIBA 12/01/2016 - "In 2005, we reported a novel Congenital Disorder of Glycosylation (CDG) termed CDG-IIf or SLC35A1-CDG, characterized by macrothrombocytopenia, neutropenia and complete lack of the sialyl-Lex antigen (NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAc-R) on polymorphonuclear cells. "